CDI Laboratories specializes in advanced proteomics and antibody profiling technologies, offering a range of products designed for comprehensive analysis of human and murine proteins. Their flagship product, the HuProt™ Microarray, features over 21,000 full-length, correctly-folded human proteins, making it the largest validated protein collection available. This microarray is complemented by their VirScan®, HuScan®, and MouseScan™ PhIP-Seq services, which enable the detection of antibodies against extensive viral and human protein sequences. These technologies facilitate high-throughput autoantibody profiling, allowing researchers to explore immune responses and identify potential biomarkers for various diseases, including autoimmune disorders and cancers.

In addition to their product offerings, CDI Laboratories provides custom monoclonal antibody development and validation services, enhancing their capabilities in antibody specificity testing and target discovery. Their focus on seromics aims to understand the unique antibody repertoires of individuals, which can significantly impact health outcomes and disease mechanisms. By leveraging their extensive antigen libraries and advanced assay technologies, CDI Labs supports biomarker discovery, patient stratification, and diagnostic development across multiple disease areas, including infectious, neurological, and genetic diseases.

Puerto Rico

CDI Labs combines proteomic libraries and synthetic biology to create Monomabs™, proteome-validated monospecific monoclonal antibodies, and the immunoprofiling service Antygen™.

CDI Laboratories

Company Details